CGRP inhibitors for migraine prophylaxis: a safety review by Rivera-Mancilla, E. et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ieds20
Expert Opinion on Drug Safety
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ieds20
CGRP inhibitors for migraine prophylaxis: a safety
review
Eduardo Rivera-Mancilla , Carlos M. Villalón & Antoinette
MaassenVanDenBrink
To cite this article: Eduardo Rivera-Mancilla , Carlos M. Villalón & Antoinette
MaassenVanDenBrink (2020) CGRP inhibitors for migraine prophylaxis: a safety review, Expert
Opinion on Drug Safety, 19:10, 1237-1250, DOI: 10.1080/14740338.2020.1811229
To link to this article:  https://doi.org/10.1080/14740338.2020.1811229
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 21 Sep 2020.
Submit your article to this journal 
Article views: 723
View related articles 
View Crossmark data
Citing articles: 3 View citing articles 
REVIEW
CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera-Mancillaa, Carlos M. Villalónb and  Antoinette MaassenVanDenBrink a
aDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The 
Netherlands; bDepartment of Pharmacobiology, Cinvestav-Coapa, Mexico City, Mexico
ABSTRACT
Introduction: Since calcitonin gene-related peptide (CGRP) plays an important role in the pathophy-
siology of migraine via the activation of the trigeminovascular system, the newest prophylactic treat-
ments directly block CGRP or its receptor. However, the safety of these novel antimigraine drugs is not 
yet sufficiently established.
Areas covered: Based on the blockade of CGRP or its receptor, this review considers: (i) the effects of 
the novel prophylactic antimigraine drugs (i.e. gepants and monoclonal antibodies) in clinical trials; and 
(ii) the potentially negative effects of blocking CGRP or its receptor in terms of safety.
Expert opinion: In the last decade, clinical trials have demonstrated the efficacy of new drugs for the 
preventive treatment of migraine which aim to (i) block CGRP or its receptor; (ii) increase tolerability as 
compared to the currently available prophylactics; and/or (iii) be more effective and safer than other 
treatments. However, these trials are limited to study the safety on the short term, and a cardiovascular 
risk with prolonged use cannot be excluded. Clearly, basic science experimental studies and long-term 
clinical trials (i.e. Phase IV) are required to delineate the safety of the newest prophylactic antimigraine 
drugs without causing unwanted side effects due to chronic CGRP (receptor) blockade.
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Migraine is a common neurovascular disorder characterized by 
recurrent moderate to severe headaches accompanied by 
nausea, vomiting, phonophobia, and/or photophobia, lasting 
from 4 to 72 hours [1,2]. Due to its high prevalence and high 
socioeconomic and personal impact worldwide, it has been 
considered as the third most prevalent disorder, the second- 
highest specific cause of disability, and the first in those 
people under 50 years of age [2,3].
The exact pathophysiological mechanisms underlying the 
onset of a migraine attack remain unclear. However, extensive 
research in the last three decades has demonstrated that 
calcitonin gene-related peptide (CGRP) plays an important 
role in the genesis of migraine via the activation of the trige-
minovascular system [4–7]. In this respect, as previously 
reported: (i) activation of the trigeminovascular system 
(which includes the meninges and intracranial blood vessels) 
results in cranial vasodilation mainly mediated by CGRP 
release [6]; (ii) serum levels of CGRP are elevated during 
migraine attacks [4]; and (iii) intravenous administration of 
CGRP produces vasodilation of the middle meningeal artery 
[12] and triggers migraine-like headaches [13,14]. These find-
ings, which further support the key role of CGRP in the patho-
physiology of migraine, indicate that CGRP and its receptor 
may be therapeutic targets for developing new antimigraine 
drugs [15].
While the triptans (which act as agonists at 5-HT1B/1D/1F 
receptors) are considered the gold standard for acute 
antimigraine treatment [16,17], some patients with a high 
frequency of migraine attacks or chronic migraine require 
prophylactic antimigraine treatment [18,19] in order to reduce 
the frequency, severity, and duration of attacks, as well as the 
associated disability [18,20,21]. This prophylactic treatment, 
which encompasses a wide variety of drugs with mechanisms 
of action unrelated to blocking the CGRPergic system, includes 
β-blockers, antiepileptics, Ca2+ channel blockers, 5-HT receptor 
antagonists, angiotensin-converting enzyme inhibitors and 
angiotensin II receptor antagonists [17,20]. It is noteworthy 
that these drugs were not originally developed for the pro-
phylactic treatment of migraine, but over time they proved 
useful in migraine management. Moreover, their specific 
mechanisms of action are not well understood and, in most 
cases, remain speculative [17].
Since migraine is related to several comorbidities (e.g. car-
diovascular, pain disorders, psychiatric, or neurological comor-
bidities) [20], the use of these prophylactic drugs should be 
considered based on the comorbidity presented by the 
migraine patient. In addition, the possibility of recurrent 
migraine attacks may result when the use of the prophylactic 
medications is withdrawn.
Interestingly, novel prophylactic antimigraine treatments, 
which directly target CGRP or its receptor, have been explored 
in the last decade (Figure 1) [15,22]. These novel antimigraine 
treatments include: (i) small-molecule CGRP receptor antago-
nists (i.e. gepants); and (ii) monoclonal antibodies targeting 
either CGRP or its receptor (see Table 1), which have now been 
approved by the Food and Drug Administration (FDA) and/or 
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by the European Medicines Agency (EMA) for the preventive 
treatment of migraine in adults. Additionally, the Spiegelmers 
(CGRP-neutralizing mirror-image L-aptamers) have been pro-
posed as a new candidate for the prophylactic antimigraine 
treatment [23]. However, to our knowledge, no further studies 
have demonstrated their antimigraine effectiveness.
Despite the highly promising potential of the gepants and 
monoclonal antibodies for the prophylactic antimigraine treat-
ment, the safety of these drugs and their mechanisms of 
action have not yet been explored in long-term trials [15,25– 
27]. Accordingly, this review attempts to provide an overview 
of the contributions of blocking CGRP or its receptor in terms 
of: (i) tolerability and safety, covering the efficacy of the new 
prophylactic antimigraine treatments (see Table 1); and (ii) the 
possible negative side effects and/or risks produced by the 
long-term blockade of the CGRPergic system.
2. CGRP and migraine
In addition to serotonin, histamine, and nitric oxide [28], CGRP 
plays an important role in the pathophysiology of migraine [4– 
7]. CGRP is a 37-amino acid neuropeptide localized in the 
peripheral and central sensory nervous system, acting as 
a potent vasodilator as well as a neurotransmitter [29,30]. 
CGRP mainly mediates its biological effects through its inter-
actions with the CGRP receptor. This canonical receptor is 
a complex of two subunits, namely: (i) a G-coupled protein 
receptor called calcitonin receptor-like receptor (CLR); and (ii) 
a receptor activity-modifying protein 1 (RAMP1) [31] (see 
Figure 2). In humans, CGRP is present in two isoforms, α- 
CGRP and β-CGRP. Since α-CGRP is the principal isoform loca-
lized in the peripheral and central sensory nervous system 
[32], its biological activity seems more important in the patho-
physiology of migraine. However, in terms of side effects, we 
cannot exclude the β-CGRP isoform (which plays a role in the 
enteric transmission) [33] since some CGRP-blocking drugs (i.e. 
monoclonal antibodies such as eptinezumab, fremanezumab, 
and galcanezumab) are not selective and can block both the 
α-CGRP and β-CGRP isoforms.
In the last decades, different studies have shown the role 
of CGRP during a migraine attack. In this respect, CGRP is 
released from the trigeminal ganglion via the activation of 
the trigeminovascular system [34]. As previously reviewed by 
Iyengar et al. [35], the trigeminal ganglion sends central 
afferent projections to the trigeminal nucleus caudalis in 
the brain stem and also to the C2 segments of the cervical 
spinal cord (trigeminocervical complex); and peripheral pro-
jections through sensory nerves, which innervate the cranial 
vasculature and the dura mater. Then, the released neuro-
peptide can bind to its receptor localized in the human 
cranial arteries producing vasodilation [36]. Furthermore, it 
Article highlights
● Migraine is a highly disabling, complex, and multifactorial neurologi-
cal disorder that involves activation of the trigeminovascular system, 
resulting in the release of CGRP from the sensory nerves.
● Although there is a wide variety of prophylactic antimigraine drugs 
that act via different mechanisms of action (e.g. β-blockers, antiepi-
leptics, Ca2+ channel blockers, 5-HT receptor antagonists, etc.), CGRP 
(receptor) blockade is critical for the novel prophylactic treatments of 
migraine.
● For prophylactic antimigraine treatment based on CGRP (receptor) 
blockade, the gepants (rimegepant and atogepant) and the mono-
clonal antibodies (erenumab, eptinezumab, fremanezumab, and gal-
canezumab) are effective and safe in the short term.
● Regarding the novel antimigraine treatments that involve CGRP 
(receptor) blockade, basic science experimental studies and long- 
term clinical trials and/or registries (Phase IV) are required to confirm 
their safety and effectiveness and to delineate their potential cardi-
ovascular side effects.
Figure 1. An overview of some antimigraine drugs that directly block CGRP or its receptor. Since CGRP plays an important role in the pathophysiology of migraine, 
in the last decades new antimigraine drugs have been developed for migraine treatment. These drugs include: (i) gepants, which act by directly blocking the CGRP 
receptor (i.e. rimegepant and atogepant); and (ii) monoclonal antibodies, which directly block CGRP (i.e. eptinezumab, fremanezumab and galcanezumab) or its 
receptor (i.e. erenumab). CLR, calcitonin receptor-like receptor; RAMP1, receptor activity-modifying protein 1.
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has been reported that CGRP concentrations in serum [4,8– 
11] and saliva [37] are elevated in migraine patients, and 
that these levels are normalized or reduced after treatment 
with triptans [8,13,14]. Moreover, intravenous injections of 
CGRP can trigger moderate to severe migraine-like 
headaches in migraine-prone patients (but not in non- 
migraine patients), suggesting that migraine patients are 
unusually sensitive to CGRP [13,14]. This approach has led 
to the development of experimental animal models for the 
study of migraine, which include, among others: (i) electrical 
Table 1. The new antimigraine drugs targeting CGRP or its receptor.
Compound
Mechanisms 









(i) Acute migraine treatment
(ii) Ongoing for prophylactic 
treatment
(i) FDA approved for the acute treatment of migraine
(ii) Ongoing phase II/III clinical trial (NCT0372368) to evaluate its 










10, 30,60 mg 
Oral
Prophylactic treatment for 
episodic and chronic migraine
(i) Phase IIb/III clinical trials









70, 140 mg 
Subcutaneous
Prophylactic treatment for 
episodic and chronic migraine
(i) The side effects were similar to placebo
(ii) FDA approved in May 2018





CGRP blocker 30, 100, 
300 mg 
Intravenous
Prophylactic treatment for 
episodic and chronic migraine
(i) FDA approved in February 2020 [72–75]
Fremanezumab 
(TEV-48,125)
CGRP blocker 225, 675 mg 
Subcutaneous
Prophylactic treatment for 
episodic and chronic migraine
(i) FDA approved in September 2018




CGRP blocker 225, 675 mg 
Subcutaneous
Prophylactic treatment for 
episodic and chronic migraine
(i) FDA approved in September 2018
(ii) EMA approved in November 2018
[86–93]
FDA, Food and Drug Administration; EMA, European Medicines Agency. 
Figure 2. Composition of the human calcitonin-family receptors and the relative affinity/potency of binding of CGRP, AM and AMY to canonical and non-canonical 
receptors. CGRP can exert its pathophysiological effects via the activation of its receptor (CGRP receptor) or via the activation of distinct CGRP-responsive receptors 
with moderate affinity/potency for AM receptors, and practically the same potency for the AMY receptors, as compared to their endogenous ligands. CGRP, 
calcitonin gene-related peptide; AM, adrenomedullin; AMY, amylin; CLR, calcitonin receptor-like receptor; CTR, calcitonin receptor; RAMP, receptor activity-modifying 
protein. Human and *rodents values of apKi, 
bpEC50, and 
cpKd [98,100].
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stimulation of the trigeminal ganglion; (ii) electrical/chemical 
stimulation of the meninges; (iii) administration of CGRP; (iv) 
genetic manipulation of CGRP [38,39]; and (v) in vivo (using 
infusions of headache-inducing substances) and in vitro 
(using isolated cranial and coronary arteries) human models 
[40]. These models have been used in an attempt to clarify 
and understand the pathophysiological mechanisms of 
migraine, as well as to carry out preclinical studies that 
lead to the development of new antimigraine drugs.
Finally, the fact that there are selective drugs targeting 
CGRP (or its receptor) with antimigraine efficacy (as dis-
cussed below), supports the link between CGRP and 
migraine [41].
3. Blockade of CGRP or its receptor as a treatment 
for migraine
Based on the background showing the role of CGRP in 
migraine, new antimigraine drugs targeting CGRP or its recep-
tor have been developed in the last decades. These new 
antimigraine drugs are focused on reducing vasodilation and 
neurogenic inflammation, relieving pain, reducing the asso-
ciated symptoms of migraine and avoiding the occurrence or 
intensity of migraine attacks. Moreover, they have been shown 
to be effective, well tolerated and safer than other drugs 
initially used in the preventive treatment of migraine.
As previously reviewed by de Vries et al. [15], antimigraine 
drugs targeting CGRP or its receptor can currently be divided 
into: (i) drugs for the acute treatment of migraine (i.e. gepants, 
which block the CGRP receptor); and (ii) prophylactic antimi-
graine drugs (i.e. gepants and monoclonal antibodies against 
CGRP or its receptor) (see Table 1).
In this respect, seven CGRP receptor blockers have been 
developed for migraine therapy. Four have been discontinued 
due to several disadvantages including: (i) poor oral bioavail-
ability (i.e. olcegepant, previously known as BIBN4096BS) [42]); 
and (ii) hepatotoxicity [i.e. telcagepant (MK-0974), MK-3207, 
and BI 44,370 TA] [43–45]. In contrast, both ubrogepant (MK- 
1602) [46] and rimegepant (BMS-927,711) [47] have been 
approved by the FDA in 2019 and 2020, respectively, for 
acute antimigraine treatment. Interestingly, rimegepant is cur-
rently undergoing a clinical trial for approval as a prophylactic 
treatment (phase II/III trial, NCT0372368) [48]. The seventh 
CGRP receptor antagonist, atogepant (MK-8031, AGN- 
241,689) is the first gepant specifically developed for the 
prophylaxis of episodic and chronic migraine [49–52].
On the other hand, next to the gepants, the monoclonal 
antibodies against CGRP or its receptor represent a new hope 
for the treatment of migraine. Currently, there are four mono-
clonal antibodies that have been approved by the FDA and/or 
the EMA for the prophylactic treatment of migraine, namely: (i) 
erenumab; (ii) eptinezumab; (iii) fremanezumab; and (iv) gal-
canezumab (see Table 1). These monoclonal antibodies 
against either the CGRP receptor (the former) or the CGRP 
receptor (the latter three) seem to be promising for the pro-
phylaxis of migraine and have been shown to be safe in the 
short term [15,25,26].
3.1. Prophylactic antimigraine treatment
As previously described, the goal of prophylactic antimigraine 
drugs is to reduce the frequency, duration and severity of 
migraine attacks and, as a result, to decrease the suffering 
and disability associated with migraine. Some of these drugs 
have been approved for use in migraine treatment since 2018 
and, due to their mechanisms of action on the trigeminal 
system, have offered specificity and tolerability over the exist-
ing classical treatments (i.e. β-adrenoceptor antagonists, anti-
epileptics, Ca2+ channel blockers or 5-HT receptor 
antagonists). Therefore, CGRP receptor antagonists (i.e. rime-
gepant and atogepant) and monoclonal antibodies against 
CGRP (eptinezumab, fremanezumab and galcanezumab) or 
its receptor (erenumab) have been shown to be effective for 
migraine treatment and seem to have fewer or no side effects 
compared to ergots, triptans, or even the existing classical 
prophylactic treatments [15,26].
3.1.1. CGRP receptor antagonists: second-generation 
gepants
Gepants are small-molecule CGRP receptor antagonists devel-
oped in the last decades for the treatment migraine. These 
small molecules, which avoid the interaction between CGRP 
and its receptor (located in the trigeminal ganglion and the 
vascular smooth muscle cells; Figure 1), can be divided into: (i) 
first-generation gepants (developed for the acute treatment of 
migraine); and (ii) second-generation gepants, used for the 
acute (i.e. ubrogepant and rimegepant) and prophylactic 
[rimegepant (ongoing clinical trials) and atogepant] treatment 
of migraine.
3.1.1.1. Rimegepant. Rimegepant (BMS-927,711) is a small- 
molecule CGRP receptor antagonist developed by Biohaven 
Pharmaceutical Holding Company Ltd., and has recently been 
approved by the FDA (February 2020) for the acute treatment 
of migraine [47].
In a Phase II clinical trial, 75, 150, and 300 mg rimegepant 
showed an excellent tolerability profile [53] (similar to that pla-
cebo), with no serious side effects (see Table 2). The results after 
2 hours rimegepant 75, 150 and 300 mg showed that the percen-
tage of pain-free patients (31.4%; 32.9%; and 29.7%, respectively) 
was significantly higher than that of the placebo group (15.3%). 
Additionally, a secondary endpoint showed that 27.9%; 25.9%; 
and 23.4% of patients treated with rimegepant 75, 150 and 
300 mg, respectively, had complete migraine freedom (i.e. pain 
freedom, and no symptoms of phonophobia, photophobia, or 
nausea) at 2 hours post-dose [53]. Based on the results obtained 
in this clinical trial, the dose of 75 mg was chosen for Phase III trials 
[54] to test its efficacy, safety, and tolerability. In this study, the 
authors reported that rimegepant 75 mg was more effective in 
21% of patients (who were pain free) compared with the placebo 
group (11%). The most common side effect in the rimegepant- 
treated patients were nausea (2–8%), vomiting (2–3%), dizziness 
(2–4%), and urinary tract infection (2–3%) [53,54]. Moreover, since 
rimegepant produced no cardiovascular side effects or hepato-
toxicity in the population [53–56], it was suggested that this 
gepant is safe for the treatment of migraine. Furthermore, the 
efficacy and safety of rimegepant as a prophylactic antimigraine 
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treatment is being evaluated through a randomized, double- 
blind, placebo-controlled, phase II/III clinical trial (NCT0372368). 
This trial will evaluate the efficacy and safety of 75 mg rimegepant 
as compared with placebo in migraine patients, with a study 
completion date of 30 January 2021 [48].
3.1.1.2. Atogepant. Atogepant (MK-8031 or AGN-241,689) is 
a CGRP receptor antagonist with a higher potency and longer 
half-life than ubrogepant (which is used for the acute treat-
ment of migraine). For this reason, its use has been proposed 
for the prevention of episodic and chronic migraine (see Table 
1) [49–52].
A Phase IIb/III randomized, double-blind, placebo con-
trolled in parallel-group study clinical trial evaluated the 
efficacy, safety, and tolerability of atogepant at different 
daily (10, 30, or 60 mg) or twice daily (30 or 60 mg) oral 
doses or placebo during 12 weeks. All active treatment 
groups showed a significant reduction in their mean 
monthly migraine/probable migraine headache days 
(−4.00 for 10 mg; −3.76 for 30 mg; −3.55 for 60 mg; and 
−4.23 or 4.14 for the twice daily 30 or 60 mg, respectively) 
compared to placebo (−2.85 days). Moreover, atogepant 
was well tolerated with not significant and/or serious side 
effects (placebo = 19.35%; atogepant 10, 30 and 60 mg 
daily = 18.28%, 25.68%, and 27.96%, respectively; or ato-
gepant 30 and 60 mg twice daily = 24.42% and 28.57%, 
respectively) and ≥5% patients presented the most com-
mon side effects, namely: nausea (5–11%), fatigue (1–10%), 
constipation (2–6%), nasopharyngitis (1–7%) and urinary 
tract infection, with not sings of hepatoxicity [49,50]. 
Currently, a Phase III clinical trial (NCT03855137) is in pro-
gress, with a study completion date of 
31 August 2021 [52].
In addition, data obtained from in vitro studies using 
human intracranial and coronary arteries showed that ato-
gepant is more effective and potent in antagonizing CGRP- 
induced vasodilation in human meningeal arteries as com-
pared with human coronary arteries, suggesting that ato-
gepant would have a safety benefit when considering 
cardiovascular side effects [57]. Obviously, long-term clin-
ical trials are necessary to fully verify the safety of 
atogepant.
Table 2. Overview of side effects reported for the prophylactuc anti-migraine drugs.




Placebo (11%); Rimegepant 75 mg (13%) [24-25]




Urinary tract infection <1 2-3
Atogepant 
(MK-8031, AGN-241689)
Placebo (19.35%); Atogepant 10 mga (18.28%), 30 mga (25.68%), 60 mga (27.96%); Atogepant 30 mgb (24.42%), 60 mgb 
(28.57%)
[30-31]
Placebo 10 mga 30 mga 60 mga 30 mgb 60 mgb
Nausea 4.84 5.38 7.10 11.29 8.14 9.89
Fatigue 3.20 1.08 1.64 2.69 2.33 9.89
Constipation 2.15 2.15 5.46 4.84 3.49 6.59




Placebo (39-63%); Erenumab 70 mg (40-58%); 140 mg (45-55%) [35-38]
Placebo 70 mg 140 mg
Injection-site pain 0.3-4 3-6 0.3-4
Fatigue 2-3 2-4 2-4
Nasopharyngitis 2-8 3-10 <3
Upper respiratory tract infection 1-6 3-7 3-5
Nausea 1-5 2-3 <3
Eptinezumab 
(ALD-403)
Placebo (45-60%); Eptinezumab 30 mg (58%); 100 mg (40-63%); 300 mg (52-58%); 1000 mg (57%) [41-43]
Placebo 30 mg 100 mg 300 mg 1000 mg
Upper respiratory tract infection 5-7 <11 4-10 5-10 9
Urinary tract infection 1-6 - <3 <4 1
Fatigue 1-4 <3 2-3 1-4 4
Nausea and vomiting 1-4 4 <2 <4 4
Fremanezumab 
(TEV-48125)
Placebo (40-65%); Fremanezumab 225 mg (46-66%); 675 mg (69-70%); 225 mg+675 mg (53-70%); 900 mg (47%) [46-49]
Placebo 225 mg 675 mg 225+675 mg 900 mg
Injection-site pain 3-28 9-30 4-30 7-26 9
Nausea 1-4 <2 <3 <2 -
Upper respiratory tract infection 4-5 4-6 2-5 <4 -
Nasopharyngitis 2-5 2-4 2-5 1-4 1
Fatigue <1 <2 2-3 - -
Urinary tract infection 1-3 <2 <4 <5 2
Galcanezumab 
(LY-2951742)
Placebo (50-63%); Galcanezumab 120 mg (51-65%); 240 mg (67-71%) [55-59]
Placebo 120 mg 240 mg
Injection-site pain 2-17 6-17 7-20
Nausea 2-4 2-8 3-6
Upper respiratory tract infection 2-9 3-11 3-15
Nasopharyngitis 2-9 6-18 2-13
Fatigue <3 <3 <3
Urinary tract infection 1-4 <4 1-6
The doses were used for the treatment of both episodic or chronic migraine during short-term trials. aDaily doses; btwice-daily doses. 
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3.1.2. Monoclonal antibodies
The development of monoclonal antibodies targeting CGRP or 
its receptor represents a strategy complementary to gepants 
for migraine treatment. Since their plasma half-life is much 
longer than that of the gepants, their use has been proposed 
and recommended by current European Headache Federation 
guidelines as prophylactic drugs to prevent episodic and 
chronic migraine attacks [58]. Nevertheless, their specific site 
and/or mechanisms of action in the trigeminal system are still 
unknown. Interestingly, as previously reviewed by Edvinsson 
et al. [59], the therapeutic effect of monoclonal antibodies can 
be completely peripheral due to its low permeability into the 
blood-brain barrier), and it is likely to affect targets within the 
trigeminovascular system [59]. Currently, there are four differ-
ent monoclonal antibodies (see above and Table 1): (i) one 
fully human monoclonal antibody (i.e. erenumab) that directly 
blocks the CGRP receptor, preventing the binding of CGRP to 
its canonical receptor; and (ii) three human monoclonal anti-
bodies that directly block CGRP (i.e. eptinezumab, fremanezu-
mab, and galcanezumab) (see Figure 1). Therefore, the 
monoclonal antibodies targeting the CGRP pathway symbolize 
a novel and specific therapeutic approach in the prevention of 
migraine.
3.1.2.1. Erenumab. Erenumab (AMG-334) is the only fully 
human monoclonal antibody that directly blocks the canonical 
CGRP receptor (see Figure 1) [60], and the first to be approved 
by the FDA (May 2018) and by the EMA (July 2018) for the 
prophylactic treatment of migraine (see Table 1) [61,62].
Data from two Phase II clinical trials have been presented. 
First, in a 12-week multicenter, randomized, double-blind, 
placebo-controlled monthly dose of 7, 21 and 70 mg erenu-
mab were tested. Only the 70 mg dose reduced the number of 
monthly headache days to −3.4 days when compared with the 
placebo group (−1.1 days) with a difference of −1.1 days 
(P = 0.021) [63]. In the second clinical trial, doses of 70 and 
140 mg produced a significant reduction in the number of 
monthly headache days, both doses −6.6 days versus placebo 
−4.2 (P < 0.0001) post-dose [64]. Furthermore, there are data 
from two Phase III clinical trials, namely, the ARISE and STRIVE 
studies. In the ARISE study (NCT02483585), 557 patients were 
randomized to monthly subcutaneous injections of 70 mg 
erenumab or placebo. The results showed a reduction in the 
number of monthly headache days at the third moth post- 
dose. In this trial, erenumab-treated patients (70 mg) showed 
a change of −2.9 days in monthly migraine days compared 
with −1.8 days for placebo-treated patients (difference of 
−1.1 days, P = 0.001); achieving a ≥ 50% reduction in monthly 
migraine days by 39.7% for erenumab 70 mg and 29.5% for 
the placebo group (P = 0.01) [65]. Similar results were 
obtained from the STRIVE study (NCT02456740), in which 
a total of 955 patients (monitored during 6 months) were 
randomized and divided into (i) 317 patients for testing ere-
numab 70 mg; (ii) 319 for testing erenumab 140 mg; and (iii) 
319 for the placebo group. Erenumab produced a reduction in 
monthly migraine days by 3.2 days in the 70 mg erenumab 
group and 3.7 days in the 140 mg erenumab group, as com-
pared with 1.8 days in the placebo group (P < 0.001). In 
addition, a ≥ 50% reduction in the monthly migraine days 
was achieved by 43.3% and 50% after erenumab 70 and 
140 mg, respectively, as compared with 26.6% in the placebo 
group (P < 0.001) [66].
On the other hand, erenumab has also been evaluated in 
the long term in episodic [67] and chronic [68] migraine 
patients. In this respect, during the open-label treatment 
phase clinical trial for episodic migraine (NCT01952574), 
patients received monthly erenumab 70 mg. After 2 years, 
the initial dose was increased to 140 mg in order to evaluate 
the long-term safety and tolerability of the higher dose. The 
side effects patient incidence rate was 132.0 per 100 patient- 
years (142.0 after erenumab 70 mg and 128.1 after erenumab 
140 mg). Moreover, the most frequent side effects in at least 
≥4.0 per 100 patient-years were (expressed in incidence rate): 
viral upper respiratory tract infection (12.9), upper respiratory 
tract infection (7.2), sinusitis (4.6), influenza (4.2) and back pain 
(4.2); these effects did not increase relative to placebo based 
on the results obtained from the placebo-controlled clinical 
trials [67]. Regarding the chronic migraine patients, an open- 
label extension study (NCT02174861) evaluated the effect of 
monthly erenumab 70 mg following erenumab 140 mg (which 
was increased between weeks 4 or 28) to evaluate the long- 
term efficacy and safety during 52 weeks [68]. The results 
showed an efficacy with a reduction in the monthly migraine 
days of 9.4 and 8.8 days at weeks 40 and 52, respectively. In 
addition, a ≥ 50%, ≥75% and ≥100% reductions in the 
monthly migraine days was achieved at week 52 by 59.0%, 
33.2% and 8.39% of patients, respectively. In terms of safety, 
the total incidence rate in erenumab-treated patients was 
126.3 per 100 patient-years, and 132.0 and 148.5 per 100 
patient-years pots-dose erenumab 70 mg and 140 mg, respec-
tively. The most common side effects (expressed as incidence 
rate per 100 patient-year) were: viral upper respiratory tract 
infection (16.4), upper respiratory tract infection (7.2), sinusitis 
(7.1) and arthralgia (4.2), which did not increase when com-
pared with the double-bind treatment phase [68].
Moreover, an in vitro study by Rubio-Beltrán et al. [69] 
showed that erenumab is capable of inhibiting CGRP- 
induced vasodilatory responses in human-isolated middle 
meningeal, internal mammary and coronary arteries. This 
monoclonal antibody showed no direct contractile or relaxant 
effects, as well as specificity at inhibiting the vasodilator 
responses to CGRP without interactions with other vasoactive 
compounds [69]. These findings seem favorable in terms of 
vascular safety. However, as discussed below, some other 
issues must be considered to adequately explore the cardio-
vascular safety of erenumab, including the interaction of CGRP 
with non-canonical receptors [31,70].
In all clinical trials, erenumab showed to be well tolerated, 
effective and safe. The most common side effects (without 
showing differences with the placebo group) (see Table 2) 
were injection-site pain (0.3–6%), fatigue (2–4%), nasopharyn-
gitis (2–11%), upper respiratory tract infection (3–7%) and 
nausea (2–3%) [63–66]. Indeed, erenumab has proven to be 
a safe monoclonal antibody for the prevention of migraine (in 
short term) since its administration does not produce cardio-
vascular side effects or hepatotoxicity (due to its route of 
administration). In addition, this monoclonal antibody for the 
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CGRP receptor resulted 5000-fold more selective for the cano-
nical receptor, as compared with other human calcitonin 
family receptors [i.e. adrenomedullin (AM), calcitonin (CT) or 
amylin (AMY) receptors] [60]. However, we cannot categori-
cally rule out whether CGRP receptor blockade will be selec-
tive in the long term or whether there will be involvement of 
non-canonical receptors. If this were the case, blocking the 
CGRP receptor with erenumab would leave the possibility 
open for CGRP to bind to the amylin AMY1 receptors, keeping 
in mind that CGRP can mediate its effects through CGRP 
receptors or distinct CGRP-responsive receptors [31]. In fact, 
it has been shown that the AMY1 receptor: (i) could potentially 
function as an additional CGRP receptor in coronary arteries 
[70]; and (ii) is located in the trigeminal system [71], which 
could suggest an important role in migraine. Nevertheless, 
further studies are necessary to elucidate the safety of erenu-
mab and its exact mechanism(s) of action (in the long term), as 
well as the role of AMY1 receptors in migraine.
3.1.2.2. Eptinezumab. Eptinezumab (ALD-403) is the first 
intravenously administered humanized monoclonal antibody 
that directly blocks CGRP. It was developed by Alder 
BioPharmaceuticals Inc. and H. Lundbeck A/S, and has recently 
been approved by FDA (February 2020) for the preventive 
treatment for migraine (see Table 1) [72].
In a first Phase II, randomized, double-bind, placebo- 
controlled clinical trial, intravenous eptinezumab (1000 mg) 
was tested for 24 weeks and showed a significant reduction in 
monthly migraine days in patients with episodic migraine as 
compared with placebo. In this respect, the mean change in 
migraine days between baseline and weeks 1–4; 5–8; and 9–12 
in eptinezumab (1000 mg) and the placebo group was −5.6 
and −3.9 days (difference of −1.7 days); −5.6 and −4.6 days 
(difference of −1.0 days); and −5.6 and −4.6 days (difference of 
−1.0 days), respectively. Furthermore, 33% of eptinezumab- 
treated patients experienced a ≥ 75% reduction in monthly 
migraine days over 12 weeks compared with 9% in the pla-
cebo group, as well as 51% of eptinezumab-treated patients 
showed ≥50% reduction in monthly migraine days compared 
to 33% in the placebo group [73]. Additionally, in a Phase III 
clinical trial, eptinezumab 30, 100 and 300 mg (PROMISE-I) or 
eptinezumab 100 and 300 mg (PROMISE-II) showed to be 
effective in reducing monthly migraine days in episodic 
migraine (PROMISE-I) by reducing the frequency of migraine 
days during weeks 1–2 from baseline to −4.0 days (30 mg); 
−3.9 days (100 mg); and −4.36 days (300 mg) when compared 
to the placebo group (−3.2 days), with a difference of −0.82; 
−0.69; and −1.11 days, respectively (P < 0.0.01) [74]; and by 
reducing the monthly migraine days in chronic migraine 
patients treated with eptinezumab (100 and 300 mg) by −7.7 
and −8.2 days, respectively, versus the placebo group 
(−5.6 days) with a difference of −2.0 and −2.6 days 
(P < 0.0001) (PROMISE-II) [75].
The most frequent side effects reported in the eptinezu-
mab-treated group were (see Table 2): upper respiratory tract 
infection (4–11%), urinary tract infection (1–3%), fatigue (2–-
4%), nausea and vomiting (1–4%); which were similar in the 
placebo group (5–7%; 1–5%; 1–4%; 1–4%; respectively, [72– 
75], with no signs of hepatotoxicity or cardiovascular side 
effects. Therefore, the results from clinical trials showed the 
efficacy, tolerability, and short-term safety of eptinezumab for 
the preventive treatment of migraine.
3.1.2.3. Fremanezumab. Fremanezumab (TEV-48,125) is 
another humanized monoclonal antibody that directly blocks 
the α-CGRP and β-CGRP isoforms [76], avoiding the binding of 
CGRP to its receptor (Figure 1). This monoclonal antibody is 
the second one to be approved by the FDA (September 2018), 
and the third one to be approved by the EMA (March 2019) for 
use in the prevention of episodic and chronic migraine (see 
Table 1) [77,78].
For episodic migraine, results from a Phase IIb clinical trial 
showed that subcutaneous doses of 225 and 675 mg (given 
once every 28 days for 12 weeks) reduced the number of 
monthly headache days by 2.81 days in the 225 mg fremane-
zumab group and 2.64 days in the 675 mg fremanezumab 
group compared to the placebo group (P < 0.001). In this 
respect, the percentage of patients treated with fremanezu-
mab 225 or 675 mg with at least 50% of reductions in 
migraine days was 53% and 59%, respectively, compared 
with the placebo group, 28% (P < 0.001) [79]. Similar results 
were obtained from a Phase III clinical trial [80]. A total of 875 
patients were randomized to monthly 225 mg injections or 
quarterly 675 mg injections of fremanezumab. The high dose 
(675 mg) produced a decrease in the number of monthly 
migraine days by 1.3 days compared to placebo, while the 
low dose (225 mg) reduced the number of monthly headache 
days by 1.5 days. Moreover, at least 50% of reduction in 
migraine days was observed at week 12 in 47% of patients 
treated with fremanezumab 225 mg; and in 44.4% of the 
patients treated with fremanezumab 675 mg (38%); compared 
with 27.9% in the placebo group (P < 0.001 when comparing 
both fremanezumab-treated groups with the placebo-treated 
group) [80].
Regarding chronic migraine, a Phase IIb clinical trial 
showed that subcutaneous administration of fremanezumab 
675 mg (in the first treatment cycle) plus 225 mg (in 
the second and third treatment cycles) produced a reduction 
in the number of monthly headache hours with 22.74 hours 
compared to placebo. Additionally, fremanezumab 900 mg (in 
all three treatment cycles) produced a decrease of 30.41 hours 
in the number of monthly headache hours compared to pla-
cebo [81]. Moreover, in a Phase III clinical trial, patients with 
chronic migraine received a quarterly subcutaneous injection 
of fremanezumab 675 mg at baseline (and placebo at weeks 4 
and 8) or a single dose of fremanezumab 675 mg followed by 
two doses of 225 mg at weeks 4 and 8. Both groups showed 
a reduction in the number of monthly headache days with 
1.8 days (quarterly 675 mg fremanezumab) and 2.1 days 
(monthly 675 mg plus 225 mg fremanezumab) compared to 
placebo. Additionally, a reduction of at least 50% in the aver-
age number of headache days per month was observed in 
38% in the fremanezumab-quarterly group; in 41% in the 
fremanezumab-monthly group; and 18% in the placebo 
group (P < 0.001 when comparing both fremanezumab- 
treated groups with placebo group) [82].
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In all cases, fremanezumab 225 and 675 mg showed to be 
safe, well tolerated and effective for the prevention of episodic 
and chronic migraine in the short term. The most common 
side effects (see Table 2) were pain at the injection site, upper 
respiratory infection, nasopharyngitis, urinary tract infection, 
fatigue, and nausea, without cardiovascular side effects or 
hepatotoxicity [76,79–85]. On this basis, it has been suggested 
that fremanezumab seems a promising option (in terms of 
safety) as a preventive treatment for migraine, even in the 
long term [85].
3.1.2.4. Galcanezumab. Galcanezumab (LY-2,951,742) is 
a humanized monoclonal antibody that directly blocks both 
the α-CGRP and β-CGRP isoforms, preventing their binding to 
the CGRP receptor (Figure 1) [86]. This monoclonal antibody 
received FDA approval in September 2018 [86] and EMA 
approval in November 2018 [87] for the prophylaxis of 
migraine in adults (see Table 1). More recently, Eli Lilly and 
Company applied for an extension of indication of galcanezu-
mab to add the prevention of attacks throughout a cluster 
period in adults with episodic cluster headache. However, EMA 
recommended the refusal of a change to the marketing 
authorization for this drug [88].
Results from a Phase IIb clinical trial for episodic migraine 
showed that i.v. administration of galcanezumab (120 mg 
given monthly during 3 months) produced a significant reduc-
tion in the monthly headache days as compared with placebo 
by −4.8 versus −3.7 days, respectively (compared to the base-
line values of 6.6 and 6.7 days, respectively). Moreover, in 
a secondary endpoint, the galcanezumab-treated patients 
(120 mg) reported 50% and 100% reduction in the number 
of monthly headache days during the third study period [89]. 
Additionally, in two Phase III clinical trials (EVOLVE-1 and 
EVOLVE-2), monthly injections of galcanezumab 120 and 
240 mg (during 6 months) produced a reduction in the 
monthly migraine headache days as compared with placebo, 
without showing differences between both doses [90,91]. In 
this respect, during the EVOLVE-1 trial, the treatment with 
galcanezumab 120 and 240 mg produced a significant reduc-
tion in the monthly migraine headache days by −4.7 and 
−4.6 days, respectively, compared with placebo (−2.8 days), 
with a difference of −1.9 days for galcanezumab 120 mg and 
−1.8 days for galcanezumab 240 mg (P < 0.001 versus placebo 
[90]. Similar results were obtained during the EVOLVE-2 trial, 
where the patients showed a reduction in the monthly 
migraine headache days by −4.3 and −4.2 days post-dose of 
galcanezumab 120 and 240 mg, respectively, compared with 
the placebo group (−2.3 days) [91]. Regarding chronic 
migraine, results from Phase II clinical trials showed that 
both doses of galcanezumab (120 and 240 mg, given subcu-
taneously) during 9 months [92] or 12 months [93] are effec-
tive in reducing the number of monthly migraine headache 
days by −4.8 and −4.6 days (when compared with placebo 
−2.7 days, P < 0.001) [92]; and by −5.6 and −6.5 days post-dose 
of galcanezumab 120 and 240 mg, respectively [93]. Likewise, 
this monoclonal antibody has been shown to be well tolerated 
since the incidence rate of side effects was low (see Table 2) 
both in patients with episodic (51–65% for galcanezumab 
120 mg; 67–71% for galcanezumab 240 mg; when compared 
with the 50–63% in the placebo group) [89–91] and chronic 
migraine (58% for galcanezumab 120 mg; 57% for galcanezu-
mab 240 mg; compared with the placebo group, 50%) [92].
4. New antimigraine treatments?
In an attempt to find new alternatives for migraine treatment, 
more recent studies have analyzed the direct effects of small 
RNA sequences on CGRP. A first approach to block the effect 
of CGRP is the use of specific CGRP-neutralizing L-aptamers or 
Spiegelmers. Indeed, next to gepants or monoclonal antibo-
dies, Spiegelmers seem to be candidates for the treatment/ 
prevention of migraine [23]. Spiegelmers are single-stranded 
mirror-image RNA oligonucleotides, which are capable of spe-
cifically binding to CGRP and of inhibiting its function [94].
In this respect, two Spiegelmers have been shown to bind 
selectively to CGRP, namely, NOX-C89 and NOX-L41. Indeed, 
NOX-C89 was shown to reduce CGRP release from the cranial 
dura mater caused by antidromic activation of meningeal 
afferents, and produced a dose-dependent inhibition of the 
electrically evoked increases in meningeal blood flow [94]. 
Moreover, NOX-L41 can inhibit both CGRP-induced cAMP for-
mation and neurogenic plasma protein extravasation in the rat 
dura mater [23]. Based on these findings, the use of these 
Spiegelmers was proposed as an alternative for the treatment 
of migraine. However, since NOX-C89 preferentially binds to 
mouse/rat CGRP than human CGRP and it is cross-reactive to 
AMY, it was considered insufficient for further clinical devel-
opment [94]. In contrast, no compelling study has yet reported 
the effectiveness of NOX-L41 in migraine, but its potential use 
has been suggested for migraine prevention [23].
On the other hand, a second approach would be the 
possibility of genetically manipulating the gene expression of 
CGRP or its receptor. Since the use of RNA interference (RNAi) 
and small interfering RNA (siRNA) have been proposed for the 
treatment of some neurological disorders, we can speculate 
that post-transcriptional silencing of CGRP could be used as 
a therapeutic tool for migraine attacks. However, in view that 
CGRP exerts protective functions, the complete silencing of 
gene may or may not be effective in the prevention of 
migraine, keeping in mind that it could alter the vascular 
function or increase the possible harmful cardiovascular con-
sequences. Therefore, we hypothesize that if the silencing of 
gene expression is an alternative for the treatment of 
migraine, it should be considered at what time and/or how 
long should the genetic silencing be applied, as well as if it is 
necessary to apply a complete or partial genetic silencing and/ 
or intermittent or continuous. This leads us to pose the ques-
tion: will genetic engineering be safe to treat migraine? This 
still remains a crucial issue that needs to be further analyzed 
before RNAi or siRNA are ready for clinical use.
5. Side effects associated with CGRP (receptor) 
blockade
An important concern related to the long-term use of CGRP 
blockers for the prophylactic treatment of migraine (specifi-
cally using monoclonal antibodies) is that CGRP acts as an 
potent vasodilator, maintaining an important role in the 
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homeostasis of the gastrointestinal [95–97] and cardiovascular 
[98] systems under pathological conditions. Therefore, long- 
term blockade of CGRP or its receptor could cause a loss of the 
protective effect of CGRP.
In this respect, since the monoclonal antibodies eptinezu-
mab, fremanezumab and galcanezumab are nonselective for 
directly blocking CGRP and can bind to the α-CGRP and β- 
CGRP isoforms [73,76,86], a long-term CGRP blockade could 
cause gastrointestinal system-related side effects (e.g. mucosal 
damage, ulcers, constipation, and/or diarrhea). Evidently, its 
long-term effects should be investigated to rule out these 
possible side effects and to verify the safety of these mono-
clonal antibodies.
Regarding the cardiovascular side effects, this issue seems 
to be relevant since migraine patients may have an increased 
cardiovascular risk [98]. While data obtained from several clin-
ical trials have shown that the four monoclonal antibodies do 
not produce cardiovascular adverse effects in the short term 
[63–66,73–76,79–84,91–93], some fatal cardio – and cerebro-
vascular events such as atherosclerosis, right thalamic infarc-
tion or transient attack of ischemia occurred during the 
evaluation of erenumab or eptinezumab [15], even during 
the long-term clinical trials [67]. It is noteworthy that most of 
these clinical trials were limited to the evaluation time of the 
treatment (no more than 2 years). In addition, although most 
short-term clinical trials to assess cardiovascular safety of 
monoclonal antibodies include patients without cardiovascu-
lar complications, data showing that erenumab 140 mg shows 
vascular safety in patients with cardiovascular disorders (i.e. 
angina and coronary artery disease) after exercise treadmill 
suggesting that inhibition of the canonical CGRP receptor 
with erenumab does not worsen myocardial ischemia [99]. 
Certainly, this study was designed with the purpose of demon-
strating the safety of erenumab including patients with cardi-
ovascular disorders. However, this study has important 
limitations that cast doubt on its validity, including that: (i) 
78% of the study population were male considering that 
migraine is a predominantly female disorder; therefore, it 
could be assumed that blocking the effects of CGRP receptor 
with erenumab may have different effects in female patients 
than in male patients; (ii) although the study included patients 
with cardiovascular diseases (i.e. stable angina, a mainly 
macrovascular disease), patients with microvascular diseases 
better represent the population at cardiovascular risk; and (iii) 
there is no evidence that intravenous infusion with erenumab 
140 mg already induces CGRP receptor blockade after 30 min 
[100]. On this basis, we consider that additional studies are still 
needed to assess the cardiovascular safety of monoclonal 
antibodies.
On the other hand, as previously reviewed by 
MaassenVanDenBrink et al. [98], women might be at 
a higher cardiovascular risk during CGRP (receptor) blockade 
than men, specifically after menopause or during preg-
nancy. Therefore, in an attempt to clarify the cardiovascular 
safety from long-term use of monoclonal antibodies and 
considering the pharmacokinetic differences over gepants 
(e.g. longer half-lives), further studies should be conducted 
in patients with cardiovascular diseases and in pregnant (or 
preeclamptic) women.
Since this experimental strategy would obviously raise ethi-
cal concerns, an approach using relevant animal models 
seems most appropriate. In this respect, several studies have 
demonstrated the effects resulting from CGRP or its receptor 
by using gepants and/or monoclonal antibodies in animal 
models. One such example is a mouse study, where 
a harmful effect of CGRP receptor blockade by olcegepant 
(1 mg/kg) or rimegepant (10 mg/kg) on cerebral ischemic 
outcome was described. Both gepants worsened ischemic 
stroke in mice with familial hemiplegic migraine type 1 via 
collateral dysfunction [101]. In addition, it has been reported 
that CGRP-induced diarrhea in C57BL/6 J mice (transgenic 
nestin/hRAMP1 mice) is blocked by anti-CGRP antibodies 
[102]. Finally, α-CGRP knockout mice model showed to have 
increased hypertension and aortic hypertrophy, suggesting 
that upregulation of CGRP plays a protective role in the vas-
cular system [103]. Notwithstanding the use of gepants and/or 
monoclonal antibodies to block the CGRPergic system has 
shown no vascular or gastrointestinal side effects in short- 
term clinical trials, the long-term effects in specific patient 
group still need to be explored.
6. Conclusion
Based on the advances in basic and clinical research, CGRP has 
emerged as one of the main targets for the treatment of 
migraine. In this respect, during the last decades, the devel-
opment of drugs for the acute or prophylactic treatment of 
migraine has been based on the direct blockade of the CGRP 
pathway, including either CGRP or the CGRP receptor. 
Regarding the new prophylactic antimigraine drugs, results 
from clinical trials have shown the gepants or monoclonal 
antibodies to be safe in the short term, and even in the long 
term in the case of erenumab. These findings could suggest 
that direct blockade of CGRP or its receptor represents a novel 
option for the prevention of this disorder, particularly in 
patients who: (i) fail to respond to other treatments: or (ii) 
have contraindications to existing treatments (i.e. triptans). In 
addition, some basic research studies have shown the ‘vascu-
lar safety’ of some of these prophylactic antimigraine drugs. 
However, we think that chronic or long-term blockade of the 
CGRPergic pathway (which has not been explored yet) for the 
prevention of migraine attacks could cause unwanted (mainly 
cardiovascular) side effects. Therefore, basic science experi-
mental studies and Phase IV clinical trials are necessary to 
further confirm the long-term safety of the new prophylactic 
antimigraine drugs.
7. Expert opinion
Migraine is a complex neurovascular disorder that requires 
specific drugs for its acute or prophylactic treatment. 
However, many patients use nonspecific drugs to alleviate 
migraine-related pain or symptoms (i.e. nonsteroidal anti- 
inflammatory drugs, analgesics, or a combination of both). In 
an attempt to improve the quality of life of migraine patients, 
new drugs have been developed in order to reduce the side 
effects produced by the classical antimigraine drugs (e.g. 
ergots and triptans). In this respect, the association of CGRP 
EXPERT OPINION ON DRUG SAFETY 1245
with the pathophysiology of migraine has led to the develop-
ment of specific drugs that directly block CGRP or its receptor 
(see Figure 1). These drugs have been shown to be safe in the 
short-term prophylactic antimigraine treatment. However, 
their mechanism(s) of action and their long-term effects with 
reference to safety have not yet been explored. Consequently, 
there are still some pending issues (described right below) to 
ensure the safety of these novel prophylactic antimigraine 
drugs.
Firstly, CGRPergic blockers are not highly ‘selective’. This 
means that some prophylactic antimigraine drugs can block 
both the α-CGRP and β-CGRP isoforms (i.e. eptinezumab, fre-
manezumab, and galcanezumab). Since β-CGRP is mainly pre-
sent in the gastrointestinal system and its function is to 
regulate the enteric tone (i.e. by maintaining the mucosal 
integrity and gastrointestinal motility [95–97]), it is reasonable 
to question whether it would be safe to block CGRP at long 
term in the gastrointestinal system. In fact, long-term CGRP 
blockade could cause damage on the gastrointestinal mucosa, 
contribute to inflammatory bowel disease, or alter gastroin-
testinal motility (which could exacerbate episodes of diarrhea 
or constipation). Therefore, it would be prudent to consider 
the appropriate treatment of migraine in patients with gastro-
intestinal disorders (including ulcers).
Secondly, CGRP plays an important role in maintaining 
cardiovascular homeostasis, by acting as a potent vasodilator. 
Moreover, migraine is associated with increased risk of cardio – 
and cerebrovascular events [98]. Within this framework, CGRP 
seems to be relevant in some vascular diseases by preventing 
hypertension [103], preeclampsia [104], cerebral ischemia 
[105], as well as myocardial infarction and heart failure after 
cardiac ischemia [106]. From this perspective, the prophylactic 
treatment with drugs that block CGRP or its receptor in 
patients with migraine turns out to be beneficial to prevent 
it. Notwithstanding, would the blockade of the CGRPergic 
system be beneficial in the long term?; or would this blockade 
trigger unwanted (cerebro)vascular events? Certainly, clinical 
trials have evaluated the safety of approved drugs for the 
prevention of migraine, reporting that patients have no cardi-
ovascular side effects. Nonetheless, these trials were con-
ducted in the short term (lasting less than 2 years) and 
excluded higher-risk patients. Hence, future clinical trials 
should include patients with preexisting cardiovascular 
disorders.
Thirdly, as shown in Figure 2 and described above, CGRP can 
also bind to CGRP-responsive receptors, namely, the AM and 
AMY receptors [31]. Since these receptors can be found in the 
trigeminovascular system [59], they may well play a role in the 
pathophysiology of migraine. However, to the best of our 
knowledge, there is no compelling evidence of their signifi-
cance. In this respect, it is noteworthy that CGRP displays: (i) 
a high-affinity/potency for the human AMY1, AMY2, and AMY3 
receptors (human pEC50 values of 8.7–10.7; 6.2–9.7; and 7.6–9.7, 
respectively); and (ii) a moderate affinity for the human AM1 and 
AM2 receptors (human pKd or pKi values of 6.0 and 6.5–6.8, 
respectively) [107]. Accordingly, CGRP receptor blockade by 
the use of gepants or monoclonal antibodies (i.e. erenumab), 
particularly in the long term, would also allow CGRP to bind to 
the AMY or AM receptors (see Figure 2). Hence, since the AMY1 
receptor is considered as a second physiological CGRP receptor 
[71], the possibility that this receptor may play a role during 
migraine attacks cannot be categorically excluded. In addition, 
the direct blockade of CGRP by using monoclonal antibodies (i.e. 
eptinezumab, fremanezumab, or galcanezumab) would allow 
the AM or AMY ligands to bind to the CGRP receptor. If this 
were indeed possible: what effects could trigger the binding of 
these vasodilators (less potent than CGRP) to the CGRP recep-
tor? In fact, even the less potent effects produced by AM or AMY 
could explain a lower risk of (cardio)vascular disorders such as 
brain injury, hypertension, and ischemic heart disease [85]. 
However, despite the fact that CGRP shows a moderate affinity 
for both the AM1 and AM2 receptors (pKd and pKi values of 6.0 
and 6.5–6.8, respectively) (see Figure 2), the role of AM in 
migraine seems less likely since intravenous administration of 
this neuropeptide fails to cause migraine (unlike intravenous 
administration of CGRP) [108]. On the other hand, AMY has 
moderate potency to bind at the CGRP receptor (pEC50 value 
of 6.63) [109] (see Figure 2) and exerts biological actions similar 
to those of CGRP. Therefore, we can question whether AMY 
plays an important role in migraine triggering or in migraine 
pathophysiology. Hence, further studies are needed in order to 
determine: (i) the potential role and the possible mechanism(s) 
of action of the non-canonical CGRP receptors and their ligands 
in migraine; and (ii) whether blocking CGRP is more effective 
than blocking its receptor, or vice versa.
Fourthly, migraine is associated with comorbid illnesses 
besides cardiovascular diseases, especially painful disorders 
which include visceral pain, myofascial pain syndromes, or 
fibromyalgia [20,110,111]. Indeed, in most short-term clinical 
trials, the patient selection criteria were strict, excluding 
patients with medical comorbidities, which can be 
a limitation to evaluate the tolerability of monoclonal anti-
bodies against the CGRPergic system. Definitively, considera-
tion should be given to whether the CGRPergic system 
blockade can be beneficial in treating pain-related comorbid-
ities such as visceral pain or fibromyalgia, keeping in mind 
that in most cases the treatment of migraine and comorbid-
ities may require two different medications [20]. Therefore, 
more long-term studies are needed to determine whether the 
monoclonal antibodies can help alleviate various pain-related 
syndromes, and even to determine their effects in migraine 
patients with a variety of comorbidities. On the other hand, 
despite the results obtained from clinical trials are promising; 
certainly there are still several limitations including the assess-
ment of anti-migraine drugs in the real-life condition. 
Recently, data from a real-life study showed a higher efficacy 
and safety of erenumab than those of the clinical trial in 
chronic migraine patients with previous preventive failures 
and with medication overuse [112,113]. Moreover, the real- 
world population could be more susceptible to the side 
effects produced by drugs to treat migraine due to their 
comorbidities [113]. Therefore, future studies should focus 
on evaluating the effect of anti-migraine drugs on real-life 
populations in order to compare the data obtained from 
short-term clinical trials, and considering the most frequent 
comorbidities and the treatment duration.
1246 E. RIVERA-MANCILLA ET AL.
Finally, the human clinical trials analyzing the monoclonal 
antibodies for migraine prevention have been carried out in the 
short term (except for erenumab, which has been evaluated in 
the long term [67,68]. Nevertheless, it is still unknown whether 
or not long-term blockade of CGRP or its receptor may generate 
few (especially cardiovascular) side effects; this is indeed 
a reasonable concern in view that the blockade of CGRP- 
induced vasodilator effects could represent potential cardiovas-
cular risks. Furthermore, another interesting issue that cannot be 
excluded is the immunological safety of monoclonal antibodies; 
in this regard, undoubtedly, there may be a potential for the 
production of autoantibodies, despite the fact that these mono-
clonal antibodies are humanized antibodies. Therefore, basic 
science experimental studies and long-term studies (i.e. Phase 
IV) in patients with cardiovascular comorbidities (e.g. obesity, 
diabetes mellitus, etc.) are required to delineate the safety of the 
new prophylactic antimigraine drugs.
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